The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain
damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs …

Alzheimer's disease (AD) belongs to a group of neurodegenerative diseases collectively
designated as “tauopathies”, because they are characterized by the aggregation of …

Alzheimer's disease (AD) is a disabling and highly prevalent neurodegenerative condition,
for which there are no effective therapies. Soluble oligomers of the amyloid-β peptide (AβOs) …

Alzheimer's disease (AD) is a progressive neurodegenerative disease with no clinically
accepted treatment to cure or halt its progression. The worldwide effort to develop peptide …

Tau aggregation is a pathological hallmark of Alzheimer's disease, Parkinson's disease, and
many other neurodegenerative disorders known as tauopathies. Tau aggregates take on …

Over 50% of all human cancers lose p53 function. To evaluate the role of aggregation in
cancer, we asked whether wild-type (WT) p53 and the hot-spot mutant R248Q could …

Due to the high aspect ratio, appealing mechanical characteristics, and various adjustable
functional groups on the surface proteins, food‐grade protein nanofibrils have attracted …

Ever since lysozyme was discovered by Fleming in 1922, this protein has emerged as a
model for investigations on protein structure and function. Over the years, several high …

To control and enhance protein functionality is a major challenge for food scientists. In this
context, research on food protein fibril formation, especially amyloid fibril formation, holds …

Abstract Background Mesenchymal stem cells (MSCs) have been explored as promising
tools for treatment of several neurological and neurodegenerative diseases. MSCs release …